National

ATC Code: L02AE02. Hormones and related agents. Gonadotropin-releasing hormone analogues.
This product has been developed based on proprietary technology owned by GP Pharm.
Dosage: 22.5 mg
Dosage form: powder and solvent for extended-release injectable suspension
Format: 1 vial of 22.5 mg and 1 syringe of 2 mL
Therapeutic indications:

• Treatment of advanced hormone-sensitive prostate cancer.
• Treatment of locally advanced hormone-sensitive prostate cancer, in combination with radiotherapy.
• Treatment of localized hormone-sensitive prostate cancer in patients at intermediate or high risk, in combination with radiotherapy.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €300.99

ATC Code: L02AE02. Hormones and related agents. Gonadotrophin-releasing hormone analogues.
This product has been developed based on patented technology owned by GP Pharm.
Dosage: 3.75 mg
Dosage form: powder and solvent for extended-release injectable suspension
Format: 1 vial and 2 mL pre-filled syringe
Therapeutic indications:

• Treatment of hormone-sensitive prostate cancer (advanced, locally advanced, or localized in combination with radiotherapy).
• Uterine fibroids.
• Endometriosis.
• Advanced breast cancer in premenopausal and perimenopausal women.
• Adjuvant treatment of early-stage hormone-sensitive breast cancer in premenopausal and perimenopausal women, in combination with tamoxifen or aromatase inhibitors.
• Ovarian protection in premenopausal women with neoplastic disease undergoing chemotherapy.
• Central precocious puberty (CPP).

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €62.05

ATC Code: H05AA02. Parathyroid hormones and analogues.
Dosage: 250 µg/mL (20 µg/80 µL).
Dosage form: solution for injection in pre-filled pen EFG.
Format: 1 pre-filled pen of 2.4 mL
Therapeutic indications:

• Treatment of osteoporosis in postmenopausal women and in men with an increased risk of fracture.
• Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men with an increased risk of fracture.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €252.16

ATC Code: L02BG04. Hormone antagonists and related agents. Aromatase inhibitors.
Dosage: 2.5 mg
Dosage form: film-coated tablet
Format: 30 tablets
Therapeutic indications:

• Adjuvant treatment for hormone receptor-positive early invasive breast cancer in postmenopausal women.
• Continuation of adjuvant treatment for invasive hormone-dependent breast cancer in postmenopausal women who previously received standard adjuvant therapy with tamoxifen for 5 years.
• First-line treatment for advanced hormone-dependent breast cancer in postmenopausal women.
• Treatment of advanced breast cancer in women in a natural or artificially induced postmenopausal endocrine state after disease relapse or progression, and who have previously been treated with antiestrogens.
• Neoadjuvant treatment for HER-2 negative and hormone receptor-positive breast cancer in postmenopausal women for whom chemotherapy is not appropriate, and immediate surgery is not indicated.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €92.10

ATC Code: H01CC01. Hypothalamic hormones. Antigonadotrophin-releasing hormones.
Dosage: 0.25 mg / 0.5 mL
Dosage form: solution for injection in a pre-filled syringe
Format:
Box with 1 pre-filled syringe
Box with 5 pre-filled syringes
Therapeutic indications:

• Prevention of premature luteinizing hormone (LH) peaks in women undergoing controlled ovarian hyperstimulation (HOC) for assisted reproductive techniques (ART).
• In clinical studies, ganirelix was used in conjunction with recombinant human follicle-stimulating hormone (FSH) or with corifolitropin alfa, a sustained follicular stimulant.

Prescription-only medicine. Not reimbursed by the SNS. RRP incl.VAT box with 1 pre-filled syringe: €23.70; RRP incl.VAT box with 5 pre-filled syringes: €118.49

ATC Code: H01BB03. Hormones from the posterior lobe of the pituitary gland. Oxytocin and analogues.
Carbetocin in pre-filled syringe. Ready to be administered to the patient.
Dosage: 100 µg
Dosage form: solution for injection in pre-filled syringe
Format: 5 pre-filled syringes of 1 mL
Therapeutic indications:

• Prevention of postpartum haemorrhage (caesarean section or vaginal delivery) due to uterine atony.

Prescription-only medicine. Not reimbursed by the SNS. RRP incl.VAT: €177.75

ATC Code: L02BG06. Hormone antagonists and related agents. Aromatase inhibitors.
Dosage: 25 mg
Dosage form: film-coated tablet EFG
Format: 30 tablets
Therapeutic indications:

• Adjuvant treatment of postmenopausal women with early-stage, estrogen receptor-positive invasive breast cancer after 2-3 years of initial adjuvant treatment with tamoxifen.
• Treatment of advanced breast cancer in natural or induced postmenopausal women whose disease has progressed after antiestrogen therapy.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €96.66

ATC Code: L02BG03. Hormone antagonists and related agents. Aromatase inhibitors.
Dosage: 1 mg
Dosage form: film-coated tablet EFG
Format: 28 tablets
Therapeutic indications:

• Treatment of advanced hormone receptor-positive breast cancer in postmenopausal women.
• Adjuvant treatment of postmenopausal women presenting with early-stage hormone receptor-positive invasive breast cancer.
• Adjuvant treatment of postmenopausal women with early-stage, hormone receptor-positive invasive breast cancer who have received adjuvant treatment with tamoxifen for a period of 2 to 3 years.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €60.09

ATC Code: G04CA52. Drugs used in benign prostatic hyperplasia. Alpha-adrenergic receptor antagonists.
Dosage: 0.5 mg/0.4 mg
Dosage form: Hard Capsule EFG
Format: 30 capsules
Therapeutic indications:

• Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
• Reduced risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €20.15

ATC Code: G04CA53. Drugs used in benign prostatic hyperplasia. Alpha-adrenergic receptor antagonists.
Dosage: 6 mg/0.4 mg
Dosage form: modified-release tablet EFG
Format: 30 tablets
Therapeutic indications:

• Treatment of moderate to severe filling symptoms (urgency, increased frequency of urination) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to monotherapy.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €30.07

ATC Code: G04CA02. Drugs used in benign prostatic hyperplasia. Alpha-adrenergic receptor antagonist.
Dosage: 0.4 mg
Dosage form: Modified-release hard capsule EFG
Format: 30 capsules
Therapeutic indications:

• Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT: €10.96

ATC Code: G04BE03. Urologicals. Drugs used in erectile dysfunction.
Dosage:
50 mg
100 mg
Dosage form: film-coated tablet EFG
Format: 4 tablets
Therapeutic indications:

• Treatment of erectile dysfunction in men.

Prescription-only medicine. Not reimbursed by the SNS. RRP incl.VAT 50 mg/4 tablets: €17.17; RRP incl.VAT 100 mg/4 tablets: €18.73

ATC Code: G04BE08. Urological preparations. Drugs used in erectile dysfunction.
Dosage:
5 mg
10 mg
20 mg
Dosage form: film-coated tablet EFG
Format:
28 tablets for the 5 mg dose
4 tablets for the 10 mg dose
4, 8 or 12 tablets for the 20 mg dose
Therapeutic indications:

• Treatment of erectile dysfunction in adult men.

Prescription-only medicine. Not reimbursed by the SNS. RRP incl.VAT 20 mg/4 tablets: €21.31; RRP incl.VAT 20 mg/8 tablets: €39.78; RRP incl.VAT 20 mg/12 tablets: €63.11; RRP incl.VAT 10 mg/4 tablets: €13.27; RRP incl.VAT 5 mg/28 tablets: €54.53

ATC Code: L02BB03. Hormone antagonists and related agents. Antiandrogens.
Dosage:
50 mg
150 mg
Dosage form: film-coated tablet EFG
Format: 30 tablets
Therapeutic indications:
Wibical 50 mg

• Advanced prostate cancer in combination with LHRH analogues or surgical castration.
• Locally advanced prostate cancer with a high risk of progression, either alone or as an adjuvant to radical prostatectomy or radiotherapy.

Wibical 150 mg

• Treatment of locally advanced prostate cancer with a high risk of progression, either alone or as adjuvant to radical prostatectomy or radiotherapy.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT 50 mg/30 tablets: €42.37; RRP incl.VAT 150 mg/30 tablets: €127.09

ATC Code: H01CB01. Hypothalamic hormones. Somatostatin and its analogues.
Dosage: 3 mg
Dosage form: powder and solvent for solution for infusion
Format: 25 vials with lyophilized powder and 25 ampoules of solvent
Therapeutic indications:

• Treatment of gastrointestinal bleeding due to the rupture of esophageal varices.
• Adjuvant in the treatment of secretory pancreatic fistulas of at least 500 mL/day.

Prescription-only medicine. Not reimbursed by the SNS. RRP incl.VAT: €726.91

ATC Code: H01CB02. Hypothalamic hormones. Somatostatin and analogues.
Dosage:
0.1 mg/mL
0.2 mg/mL
0.5 mg/mL
Dosage form: Injectable and infusion solution
Format:
5 ampoules of 1 mL for doses of 0.1 mg/mL and 0.5 mg/mL
1 vial of 5 mL for the dose of 0.2 mg/mL
Therapeutic indications:

• Treatment of patients with acromegaly.
• Relief of symptoms associated with functional gastro-enteropancreatic endocrine tumors (GEPs).
• Prevention of complications after pancreatic surgery.
• Arresting bleeding caused by gastroesophageal varices in patients with cirrhosis.
• Treatment of TSH-secreting pituitary adenomas.

Prescription-only medicine. Reimbursed by the SNS. RRP incl.VAT 0.1 mg/mL (5 ampoules of 1 mL): €10.83; RRP incl.VAT 0.2 mg/mL (1 vial of 5 mL): €21.67; RRP incl.VAT 0.5 mg/mL (5 ampoules of 1 mL): €54.17